These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 25420695)

  • 1. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
    Soulie C; Peytavin G; Charpentier C; Lambert-Niclot S; Sayon S; Visseaux B; Simon A; Katlama C; Yazdanpanah Y; Descamps D; Calvez V; Marcelin AG
    AIDS Res Hum Retroviruses; 2015 May; 31(5):475-8. PubMed ID: 25420695
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with virological response to a switch regimen containing maraviroc for antiretroviral-experienced HIV-1-infected patients.
    Bocket L; Peytavin G; Alidjinou EK; Ajana F; Choisy P; Lê M; Charpentier C; Descamps D; Yazdanpanah Y; Katlama C; Simon A; Calvez V; Marcelin AG; Soulie C
    J Antimicrob Chemother; 2016 Sep; 71(9):2651-3. PubMed ID: 27234463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
    Mills A; Mildvan D; Podzamczer D; Fätkenheuer G; Leal M; Than S; Valluri SR; Craig C; McFadyen L; Vourvahis M; Heera J; Valdez H; Rinehart AR; Portsmouth S
    J Acquir Immune Defic Syndr; 2013 Feb; 62(2):164-70. PubMed ID: 23187936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virological and immunological response to antiretroviral regimens containing maraviroc in HIV type 1-infected patients in clinical practice: role of different tropism testing results and of concomitant treatments.
    Rossetti B; Bianco C; Bellazzi LI; Bruzzone B; Colao G; Corsi P; Monno L; Pagano G; Paolucci S; Punzi G; Setti M; Zazzi M; De Luca A
    AIDS Res Hum Retroviruses; 2014 Jan; 30(1):17-24. PubMed ID: 23971941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.
    Nelson M; Fisher M; Gonzalez-Garcia J; Rockstroh JK; Weinstein D; Valdez H; Mayer H; van der Ryst E; Goodrich JM; Dang N
    HIV Clin Trials; 2010; 11(3):145-55. PubMed ID: 20736151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological factors associated with outcome of dual maraviroc/raltegravir therapy (ANRS-157 trial).
    Soulié C; Assoumou L; Darty M; Rodriguez C; Donati F; Sayon S; Peytavin G; Valantin MA; Caby F; Schneider L; Canestri A; Costagliola D; Katlama C; Calvez V; Marcelin AG;
    J Antimicrob Chemother; 2015 Dec; 70(12):3339-44. PubMed ID: 26396157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
    Pett SL; Amin J; Horban A; Andrade-Villanueva J; Losso M; Porteiro N; Sierra Madero J; Belloso W; Tu E; Silk D; Kelleher A; Harrigan R; Clark A; Sugiura W; Wolff M; Gill J; Gatell J; Fisher M; Clarke A; Ruxrungtham K; Prazuck T; Kaiser R; Woolley I; Arnaiz JA; Cooper D; Rockstroh JK; Mallon P; Emery S;
    Clin Infect Dis; 2016 Jul; 63(1):122-32. PubMed ID: 27048747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load.
    Vitiello P; Brudney D; MacCartney M; Garcia A; Smith C; Marshall N; Johnson M; Geretti AM
    Intervirology; 2012; 55(2):172-8. PubMed ID: 22286889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice.
    Potard V; Reynes J; Ferry T; Aubin C; Finkielsztejn L; Yazdanpanah Y; Costagliola D;
    PLoS One; 2015; 10(12):e0144746. PubMed ID: 26714012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
    Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
    N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
    Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
    Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.
    Di Biagio A; Rusconi S; Marzocchetti A; Signori A; Schiavetti I; Bruzzone B; Monno L; Punzi G; Colao MG; Penco G; Zazzi M; De Luca A;
    J Med Virol; 2014 Oct; 86(10):1648-55. PubMed ID: 25042976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.